NEW YORK (GenomeWeb) – Epigenomics on Thursday lowered its revenue guidance for 2017 to a range of between €1 million ($1.1 million) and €1.5 million from a previous guidance of about €2.5 million.

The firm attributed the change to lower-than-expected revenues for the first half of the year, about €500,000, and added that it anticipates a continued lack of reimbursement coverage for the rest of the year in the US. In May the firm reported a 5 percent drop in revenues for the first quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.